Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors

The human platelet antigen-1 (HPA-1, Pl(A)) polymorphism has been proposed to influence the inhibitory actions of abciximab. Thus, we hypothesized that this polymorphism might also be the cause for paradoxical activation of platelets by GPIIb/IIIa inhibitors. The effects of abciximab (1-10 mug/ml), tirofiban (3-30 nM), or eptifibatide (0.3-3 mug/ml) on basal and ADP (3 muM)-induced CD62P externalization were measured in n = 62 healthy blood donors and n = 177 patients with stable coronary artery disease. All subjects were genotyped for the human platelet antigen-1 (HPA-1, pl(A)) polymorphism by GALIOS(R) and fluorescence correlation spectroscopy. Although a significant platelet hyperreactivity was observed in the patients, the HPA-1 genotype did not influence basal or ADP-induced CD62P expression. A moderate (twofold) stimulation of CD62P expression by abciximab but not by tirofiban or eptifibatide was observed in one patient. Interestingly, this patient carried the HPA-1 b/b genotype. In no other subject any activation of platelets by GP IIb/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or ADP-stimulated CD62P expression. It is concluded that paradoxical platelet activation by abciximab is a rare (<2%) phenomenon. HPA-I b/b genotype might be a contributing factor but clearly does not predict platelet activation by GP IIb/IIIa inhibitors. (C) 2002 Published by Elsevier Science Ltd.